Aclarion, Inc. announced that CEO Brent Ness will attend LSI USA 2026, a leading conference for MedTech innovators, investors, and industry leaders scheduled for March 16-20, 2026 in Dana Point, California. During the event, Ness will meet with investors and potential partners to discuss the company's progress with Nociscan, its proprietary magnetic resonance spectroscopy platform that uses augmented intelligence algorithms and biomarkers to help physicians distinguish between painful and non-painful discs in patients with chronic low back pain.
The significance of this announcement lies in the potential impact of Nociscan on the diagnosis and treatment of chronic low back pain, a condition affecting millions worldwide and representing a substantial healthcare burden. By providing physicians with clearer insights into the specific source of a patient's pain, the technology could lead to more targeted and effective treatment strategies, potentially reducing unnecessary procedures and improving patient outcomes. The company describes Nociscan as the first evidence-supported SaaS platform to noninvasively help physicians make this critical distinction.
For more information about Nociscan, the company maintains a website at https://www.aclarion.com where additional details about the technology are available. The platform works by receiving MRS data from MRI machines via a cloud connection, where proprietary signal processing techniques extract and quantify chemical biomarkers associated with disc pain. This biomarker data is then analyzed by AI algorithms to indicate whether a disc may be a pain source.
Ness's participation in LSI USA 2026 represents an opportunity to advance partnerships and investment in a technology that addresses a significant unmet need in healthcare. Chronic low back pain represents a major market opportunity, and improved diagnostic tools could influence treatment protocols across the medical industry. The conference format, focused on in-person meetings between innovators and investors, suggests Aclarion is actively seeking to accelerate the adoption and development of its technology.
The company's latest news and updates are available through its newsroom at https://tinyurl.com/aconnewsroom. As Aclarion continues to develop its technology and pursue regulatory and commercialization activities, events like LSI USA 2026 provide crucial platforms for connecting with the investment and partnership networks necessary to bring innovative medical technologies to market. The broader implication is that successful adoption of such AI-enhanced diagnostic tools could signal a shift toward more precise, data-driven approaches in pain management and orthopedic care.
